We therefore sought to elucidate the mechanism(s) underlying acquired resistance to ALK inhibitors in ALKF1174L-driven NB as a means to uncover secondary targets that could be exploited to prolong responses in these patients. The gene discussed is ALK; the disease is neuroblastoma.